Nanobiotix Stock Surges +800% Over the Year, Defying a Declining CAC 40
Nanobiotix significantly advanced this Wednesday, driven by a notable upward momentum over recent months. The stock of the French biotech specializing in nanomedicine is trading around €27.16 in mid-afternoon, in a slightly declining Parisian market.
Contrary Movement in a Declining Market
Nanobiotix stock has gained 3.11% compared to the previous day's close (€26.34), moving against a CAC 40 that is down 0.39% during the session. This rebound follows a week of consolidation, with the stock having lost 2.58% over the last seven days. Today's progress is set against a backdrop of favorable conditions linked to the presentation on Monday of new preclinical data on its nanoprimer platform at the annual congress of the American Association for Cancer Research (AACR). These results concern the combination of this technology with DNA immunotherapies delivered by lipid nanoparticles. This scientific communication enhances the company's visibility within the international oncological community. Over three months, Nanobiotix's valuation has jumped by nearly 56%, while the annual performance exceeds 800%. These figures reflect a profound revaluation of the stock, which now operates well above its 200-day moving average, located at €16.99. Meanwhile, the European biopharmaceutical sector shows more mixed performances this Wednesday: Sanofi is nearly stable (+0.09%), while UCB is down by 1.74%.
Technical Perspective on Stock Performance
From a technical standpoint, the price of €27.16 is positioned in the middle of the Bollinger Bands, between the upper bound at €29.02 and the lower bound at €24.61, reflecting a neutral position away from overbought or oversold zones. The Relative Strength Index (RSI) at 49 confirms this balance: this relative strength indicator, which oscillates between 0 and 100, signals an absence of marked directional tension when it remains around 50. The stock is trading above its 20-day (€26.81) and 50-day (€25.85) moving averages, indicating a short- and medium-term upward trend. The next resistance threshold identified is at €33.50, approximately 23% above the current price. On the support side, the technical floor to watch in case of a pullback is at €25.25. The monthly volatility, measured at 23.59%, remains high, characteristic of mid-sized biotechnological stocks.
